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Abstract
Background: We describe the temporal variation in viral agents detected in influenza like illness (ILI) patients before and
after the appearance of the ongoing pandemic influenza A (H1N1) (pH1N1) in Peru between 4-January and 13-July 2009.
Methods: At the health centers, one oropharyngeal swab was obtained for viral isolation. From epidemiological week (EW) 1
to 18, at the US Naval Medical Research Center Detachment (NMRCD) in Lima, the specimens were inoculated into four cell
lines for virus isolation. In addition, from EW 19 to 28, the specimens were also analyzed by real time-polymerase-chain-
reaction (rRT-PCR).
Results: We enrolled 2,872 patients: 1,422 cases before the appearance of the pH1N1 virus, and 1,450 during the pandemic.
Non-pH1N1 influenza A virus was the predominant viral strain circulating in Peru through (EW) 18, representing 57.8% of
the confirmed cases; however, this predominance shifted to pH1N1 (51.5%) from EW 19–28. During this study period, most
of pH1N1 cases were diagnosed in the capital city (Lima) followed by other cities including Cusco and Trujillo. In contrast,
novel influenza cases were essentially absent in the tropical rain forest (jungle) cities during our study period. The city of
Iquitos (Jungle) had the highest number of influenza B cases and only one pH1N1 case.
Conclusions: The viral distribution in Peru changed upon the introduction of the pH1N1 virus compared to previous
months. Although influenza A viruses continue to be the predominant viral pathogen, the pH1N1 virus predominated over
the other influenza A viruses.
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Introduction
The influenza virus causes significant morbidity and mortality
worldwide [1]. In 1998, a sentinel surveillance system of influenza
and other respiratory viruses was established by the Ministry of
Health (MoH) of Peru, and in 2006 the surveillance system’s
coverage was expanded to include additional surveillance sites [2].
Influenza circulation in Peru has been detected throughout the
whole year during 2006 to 2008 [3] and within that period a total
of 6,308 patients with influenza-like illness (ILI) were enrolled in
this passive surveillance study. At least one respiratory virus was
isolated from 2,688 (42.6%) of the patients, with etiologies varying
by age and geographical region. Influenza A (25%) was the
predominant viral respiratory pathogen in the country; however,
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during epidemiological weeks (EW) 11 and 27 in 2007. In addi-
tion, parainfluenza viruses (3.2%), adenovirus (1.8%), respiratory
syncytial virus (0.6%), enterovirus (0.5%), herpes virus (HSV;
2.6%) and other viruses (0.1%) were isolated from patient speci-
mens, which collectively contributed to 8.8% of all ILI cases [3].
As a response of the 2009 WHO global influenza pandemic
alert, the MoH of Peru intensified surveillance efforts and on May
2009, the first confirmed case of pH1N1 was identified in a
Peruvian citizen returning from New York with a respiratory
illness. Following this event, the pH1N1 quickly spread throughout
the country [4,5]. In addition, on May 2009, MoH of Peru started
an intensive influenza vaccination campaign. During the pan-
demic, laboratory diagnosis was only conducted by the Instituto
Nacional de Salud (INS-MoH) and the US Naval Medical
Research Center Detachment (US NMRCD) using the newly
described real-time RT-PCR (rRT-PCR) assay [6]. The US
NMRCD laboratory provided laboratory support by processing
samples from sentinel surveillance sites while INS-MoH focused
on processing samples from other sites in Peru.
Here we report a detailed description of the changes in the viral
agent distribution pattern from the sentinel surveillance system
before and after the appearance of pH1N1 in Peru.
Methods
Case definition and study population
AnILI casewasdefined asanypersonwithasuddenonsetoffever
($38uC) and cough or sore throat fewer than five days in duration,
with or without general symptoms such as myalgias, prostration,
headache, or malaise. [7]. The study population included every
patient with ILI, regardless of age, who sought attention in
participating health centers from January 4
th to July 13
th 2009.
NMRCD recruited patients (outpatient or inpatient) in 38
hospitals and health centers in 14 cities located in 11 provinces.
Sites in the other 14 provinces of Peru were covered by INS-MoH.
Clinics were located in northern coastal cities (Tumbes, Piura and
Trujillo), southern highlands (Arequipa, Cusco and Puno), jungle
region (Iquitos, Puerto Maldonado, Junin and Pucallpa) and
central coast (Lima) [3]. Specimens from Lima were collected from
patients reporting to the Social Security (EsSalud) Hospital and
general hospitals maintained by the Peruvian Army, Navy, Air
Force, and Ministry of Health. Hospitalization was defined as a
patient spending at least one night in the hospital or healthcare
center. Both inpatients and outpatients were enrolled.
Specimens and data collection
Data were collected at the time of medical attention using a case
report form (CRF) from all patients who met the case definition
criteria. The variables analyzed in our study are shown in Table 1.
Viral isolation during this surveillance system was only performed
in NMRCD laboratory. Samples included in this report were
collected in NMRCD’s sites.
One oropharyngeal swab was collected from each patient and
stored at 270uC until it could be transported, on dry ice, to Lima
by plane or car. At NMRCD in Lima, the specimens were
analyzed by rRT-PCR as previously described by the CDC [6]
Furthermore, samples were inoculated into four cell lines for virus
isolation and identification by immunofluorescence assay (IFA) as
previously described [3]. Influenza A virus isolates were defined as
non-pH1N1 when the specific rRT-PCR for the novel influenza
virus was negative but virus isolation for Influenza A was positive.
Further subtyping of these viruses was performed in 111 samples
(83 from EW 1 to18 and 28 from EW 19 to 28).
A sample was considered positive for pH1N1 virus when rRT-
PCR was positive regardless of the virus isolation result. A co-
infection was defined as more than one virus present in cell culture.
Two time periods were assessed in our analysis EW 1–18 (1
st
period) and EW 19–28 (2
nd period). These periods correspond to
the time intervals before and soon after the first novel influenza
cases appeared in Peru. The clinical-epidemiological forms were
entered into a database created in Microsoft (MS) Office Access
2003. Furthermore, the database here analyzed was shared with
the Epidemiology Directorate at the Peruvian MoH.
Proportions were compared using a Chi-square test (X
2).
Continuous variables with a normal distribution were compared
using the Student’s t-test (t); otherwise, the Mann-Whitney (U) test
Table 1. Characteristics of the study population, by period,
January–July 2009.
EW 1 to 18 EW 19 to 28
CHARACTERISTICS OF STUDY
POPULATION Count % Count %
Number of patients enrolled 1422 100.0 1450 100.0
Respiratory virus positive patients 505 35.5 730 50.3
Positive for pH1N1 virus 0 0.0 395 27.2
Positive for influenza A non-pH1N1 316 22.2 128 8.8
Gender*
Male 176 55.7 251 48.0
Age*
Mean, 6Std 19.2,616.5 17.9, 614.9
Median, [range] 16, [0,69] 13, [0,87]
Total 315 22.2 520 35.9
0–4 75 23.8 57 11.0
5–14 72 22.9 237 45.6
15–29 96 30.5 133 25.6
30–44 41 13.0 56 10.8
45–59 21 6.7 28 5.4
.=60 10 3.2 9 1.7
missing 01 03
Regions*
Lima 11 3.5 346 66.2
Northern Coast 167 52.8 58 11.1
Southern Highlands 10 3.2 112 21.4
Jungle region 128 40.5 7 1.3
Travel (within 7 days of symptoms
onset)
30 9.5 50 9.6
Vaccination history 5 1.6 62 11.9
Hospitalized 2 0.6 50 9.6
Medical attention before enrollment 112 35.4 246 47.0
Previous treatment
Antibiotics 44 13.9 117 22.4
Others 4 1.3 22 4.2
No treatment 251 79.4 313 59.8
Military population 28 8.9 14 2.7
*From influenza positive patients.
Table 1 shows the total number of patients enrolled in the study, the number of
positive cases for at least one virus by isolation or rRT-PCR and describes
general characteristics of non-pH1N1 influenza A cases and pH1N1 cases.
doi:10.1371/journal.pone.0011719.t001
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PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11719Figure 1. The temporal viral distribution by epidemiological week (EW) in Peru, January 4 to July 13, 2009.
doi:10.1371/journal.pone.0011719.g001
Figure 2. Distribution of viral etiology among regions according to epidemiological week. Peru, January 4 to July 13, 2009.
doi:10.1371/journal.pone.0011719.g002
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cant. Analyses were conducted using SPSS software version 17.0
(SPSS Inc., Chicago, IL).
Ethics statement
This surveillance protocol was conducted according to the
principles expressed in the Declaration of Helsinki and was
approved as less than minimal risk research by the NMRC
Institutional Review Board (IRB) and the Peruvian MoH
(NMRCD.2002.0019), written consent forms were not required.
Stamped, approved information sheets were used in place of
written consent forms.
Results
A total of 2,872 patients were enrolled in this study (Table 1). A
total of 1,422 patients were recruited during surveillance activities
before the appearance of pH1N1 (EW 1–18), and 1450 patients
were recruited during the pandemic period (EW 19–28). Before
the appearance of novel virus, non-pH1N1 influenza A virus
predominated throughout the country. The age of patients ranged
from #1 to 87 y with a median age of 16 and 13 y (mean age of 19
and 17.9 y) before and after the identification of the first pH1N1
case in Peru, respectively (U,p.0.05).
Until EW 18, a total of 505 (35.5%) patients were positive for
respiratory viruses by virus isolation, and from EW 19–28 a total
of 730 (50.3%) patients were positive for respiratory viruses by
isolation or rRT-PCR (X
2,p ,0.001) (Table 1).
During the 1
st period, 62.6% (316/505) patients were positive
for non-pH1N1 and in the 2nd period this number decreased to
17.5% (128/730); also in this period 54.1% (395/730) patients
were positive for pH1N1 virus. Based on our data (n=111), the
dominant influenza A non-pH1N1 strain prior to week 19 was
subtype H1N1 (A/Brisbane/59/07-like) until EW 8 (February
2009), however, by EW 9 (March, 2009) the dominant subtype
was H3N2. During the whole 2
nd period the influenza A non-
pH1N1 dominant subtype was H3N2 (A/Brisbane/10/07-like).
There was a 7-fold increase in seasonal influenza vaccination
rates after the appearance of the pandemic virus (X
2,p ,0.001).
This increase in vaccination rates was highest among 5–14 year-
olds (22 cases) followed by 25–29 year-olds (16 cases) with
influenza diagnosis. An increase in patients seeking medical
attention was also observed following the appearance of pH1N1
virus (Table 1, 35.4% vs. 47.0%, before and after; X
2,p ,0.001),
which correlated with an increase in the number of hospitaliza-
tions during the pandemic period (0.6% vs. 9.6%, before and after;
X
2,p ,0.001) (Table 1). The most common clinical symptoms
reported by patients were fever, cough, malaise, rhinorrhea, and
Figure 3. Distribution of Influenza A pH1N1 among regions according to epidemiological week. Peru, May 10 January to July 13,
2009.
doi:10.1371/journal.pone.0011719.g003
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difference between the clinical characteristics of patients infected
with the pH1N1 virus and those of patients infected with any other
respiratory virus including non-pH1N1 influenza A (X
2,p .0.05);
however, patients infected with RSV experienced more wheezing
cough than patients infected with other viruses (X
2,p ,0.001).
Temporal distribution of viral agents
The temporal distribution of viral agents from confirmed cases
identified at study sites nationwide is shown in Figure 1.
Before EW 18, non-pH1N1 predominated throughout the
country. Although pH1N1 cases began to be detected at the end of
EW 18, it was until EW 24 that the number of cases increased
considerably and slightly surpassed those of non-pH1N1. Between
EW 25 and EW 27, the pH1N1 virus predominated over other
viruses (Figure 1).
Update information. Figure S1 shows epidemiological data
for all weeks, through the end of 2009.
Viral distribution by region
Prior to the appearance of pH1N1, non-pH1N1 and adenovirus
were the main viruses isolated regularly from the northern coast.
Non-pH1N1 was also the main virus isolated from jungle region.
In contrast, few viruses were isolated from patients in Lima and
the southern highlands (Figure 2).
After EW 18, pH1N1 cases were mainly diagnosed in the
capital city of Lima followed by Cusco (southern highlands) and
Trujillo (northern coast). In contrast, very few pH1N1 cases were
diagnosed in jungle cities (Figure 3). For instance, the city of
Iquitos (jungle) experienced the highest number of influenza B
cases and only one pH1N1 case (Figure and Table 2).
Viral Etiology before and after the appearance of the
pH1N1 virus
Prior to the appearance of the pH1N1 virus, 547 positive results
were obtained from 505 positive patients (42 patients had co-
infections). Non-pH1N1 was the predominant viral etiology
comprising 57.8% of the confirmed cases (Figure 4A). From EW
19 to 28, the pH1N1 virus was the most prevalent (51.5%)
followed by non-pH1N1 (16.7%) (Figure 4B).
Viral distribution across age groups
Prior to the appearance of the pH1N1, the most common viral
etiologies in all the groups, was non-pH1N1 cases. Figure 5A
shows the distribution: non-pH1N1 (35%), adenovirus (20%) and
RSV (14%). Influenza B was only detected in 3.8% of cases. The
greater 30 years age groups had the highest percentages of non-
pH1N1 cases.
After the EW 18, pH1N1 predominated in all age groups except
for the infants (0–4 years). In that age group, the non-pH1N1
decreased to 20% (X
2,p ,0.001) and the pH1N1 virus comprised
13.6% of the cases (Figure 5B).
In children 5–14 y, non-pH1N1 decreased from 57.1% to
13.9% after the introduction of the pH1N1 virus. Therefore,
pH1N1 influenza cases comprised 66% of the cases. This
pattern was also observed among 15–59 year olds. (Figure 5A
and 5B).
After EW 18 an increased number of influenza B cases were
found among those 30–59 y (Figure 5B). These cases were mostly
located in Iquitos (jungle region) where only one case of pH1N1
was diagnosed (Figure and Table 2).
Half of the patients with pH1N1 (n=196) were between 5–14
years old and 106 (27%) were between 15–29 years of age.
Co-infections
Before the appearance of the pH1N1 a total of 42 (2.9%)
samples had co-infections by isolation. The most frequent co-
infections identified were: adenovirus with enterovirus (11
samples), non-pH1N1 influenza A and HSV (11 samples), and
non-pH1N1 influenza A and adenovirus (4 samples). After the
appearance of the novel virus, 36 (2.50%) samples had co-
infections. In nine pH1N1-positive samples viral co-infections were
observed, including 7 co-infections with HSV, 1 with an
enterovirus, and 1 with a parainfluenza virus. Viral co-infections
were observed for seven non-pH1N1 influenza-positive samples,
including 3 co-infections with an enterovirus, 3 with HSV, and 1
with RSV. Frequent HSV-enterovirus co-infections (n=5) were
also identified.
Figure 4. Viral etiology before and after the appearance of the
novel pH1N1 virus in Peru. January 4 to July 13 2009. A) Before
the appearance of the novel pH1N1 virus, a total of 547 positive results
were obtained from 505 positive patients; co-infections were found in
42 samples. B) After the appearance of the novel pH1N1 virus, a total of
767 positive results were obtained from 730 positive patients; co-
infections were found in 37 samples.
doi:10.1371/journal.pone.0011719.g004
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Prior to the introduction of this novel influenza virus, our
surveillance activities (2006–2008) identified Influenza A as the
predominant viral etiology among ILI patients in Peru [3]. In
2009, based on our data, the dominant influenza A non-pH1N1
strain prior to EW 19 was subtype H1N1; this subtype
predominated over subtype H3N2 from January through
February 2009. However, by March the dominant subtype was
H3N2. Interestingly, upon the introduction of the pH1N1, the
viral distribution pattern changed compared to the non-pandemic
period. Even though influenza A continued to be the predominant
viral pathogen, non-pH1N1 influenza A viruses were also rapidly
displaced from their predominance by pH1N1. Our data tend to
support higher transmission potential of pH1N1 than non-pH1N1
influenza A viruses, as reported elsewhere [4,8,9]. This phenom-
enon could be partially explained by higher population suscepti-
bility to pH1N1 than non-pH1N1 virus to which the population
might have acquired partial immunity in previous years via prior
natural exposure with antigenically-related strains and annual
immunization campaigns of a fraction of the high-risk population,
with live attenuated vaccines [10,11,12]. A well-known result in
theoretical epidemiology is that in a population challenged by
multiple infectious agents, the one with the highest reproduction
number (fitness) will dominate the transmission dynamics [13].
The reproduction number implicitly accounts for the intrinsic
virus transmissibility and the background population immunity. In
an earlier report [4,8,9] we estimated the reproduction number
from the initial pandemic growth phase in the range 1.2–1.7,
which is in good agreement with estimates of the reproduction
number of inter-pandemic influenza in temperate countries [10].
During the study period, Lima and the southern highlands
(Cusco) experienced a more profound impact from the pandemic
than other Peruvian regions, going from less than ten cases of ILI
per week before, to more than ten cases per week after the
pandemic onset. Prior to the appearance of the pH1N1 virus, the
majority of these cases were caused by non-pH1N1 influenza A
and adenoviruses. The more tropical jungle and northern coastal
regions with regular viral isolation did not experience a similar
increase in ILI cases, although these geographical regions noticed
a change in distribution of detected viruses, from EWs 19–28.
Our data show that influenza positive cases were more frequent
among children under 14 y before and after the appearance of the
new virus and confirm that the pH1N1 virus in Peru was more
frequent among 5–14 y ILI patients [4], which is in agreement
with reports from Chile [14]. In other South American countries
like Chile, circulation of pH1N1 was first detected after EW 20
(May 17, 2009) and before that week RSV, parainfluenza viruses,
Figure 5. Distribution of viral etiology across age groups before and after the appearance of the novel pH1N1 virus in Peru,
January 4 to July 13, 2009. A) Before the appearance of pH1N1 virus a total of 544 positive results were obtained from 505 positive patients
(missing=3). B) After the appearance of the pH1N1 a total of 763 positive results were obtained from 730 positive patients (missing =4).
doi:10.1371/journal.pone.0011719.g005
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patients with ILI. Moreover increased circulation of the novel
influenza virus reached up to 64% of viral isolations at EW27 [15].
In our data, the lower frequency of pH1N1 viral cases among
.60 y suggests relative protection for persons who were exposed
to H1N1 strains during childhood prior to the 1957 pandemic
[16]. However, the number of cases of non-pH1N1influenza A
was also low in the same group possibly due to the vaccination
campaign initiated by the MoH, complicating the interpretation of
our data.
One shortcoming of a sentinel surveillance program is the
potential for sampling and selection bias. Therefore our results
may not be representative of the entire population of Peru. Hence,
this potential bias and the lack of reliable population data preclude
us from calculating incidence rates [3]. However, one advantage
provided by sentinel surveillance systems is the ability to identify
increasing trends in the number of patients seeking medical
attention due to ILI symptoms and identifying the viruses related
to such increases using fewer resources than a population-based
study require.
We found significant changes in hospitalization rates following
the introduction of the pandemic virus. This maybe explained by
increased awareness among the population about the presence of
the new virus in addition to the global alarm on pandemic risk. Of
note we did not focus in the long-term follow-up of patients to
determine post-enrollment complications and hospitalization rates.
Reports of seasonal influenza vaccination rates increased 7-fold
following the appearance of the pH1N1 influenza virus. This
increase in vaccination rates could explain the drop in non-pH1N1
influenza A. However, the seasonal influenza vaccination policy in
Peru was focused on individuals under 2 y and over 60 y. Hence,
the drop in the number of non-pH1N1influenza A cases was most
likely driven by strain competition dynamics with the pH1N1, and
not by vaccine intervention.
Influenza-like illness circulation will continue to be monitored
throughout Peru, to determine when the novel influenza virus
reaches non-epidemic levels and detect any further changes in the
viral distribution pattern particularly on the fast approaching
winter season.
In the pandemic, the viral distribution in Peru changed upon
the introduction of the pH1N1 virus compared to previous
months. Although influenza A viruses continue to be the
predominant viral pathogen, the pH1N1 virus predominated over
the other influenza A viruses.
Supporting Information
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Found at: doi:10.1371/journal.pone.0011719.s001 (0.93 MB TIF)
Acknowledgments
We would like to express our gratitude to the people of Direccio ´n General
de Epidemiologı ´a, the Peruvian national network of epidemiology and the
virology laboratory and database personnel of US NMRCD in Peru for all
their hard work during this pandemic.
Peru Influenza working group
Gloria Chauca, Jane Rı ´os, Merly Sovero: NMRCD, Moise ´s Apolaya:
Direccio ´n de Salud de la Fuerza Ae ´rea; Nelly Quinteros: Instituto Nacional
de Bienestar Familiar (INABIF). Jackeline Aspajo: Hospital 2 de Mayo-
Lima; Silvia Macedo: Tumbes; Mo ´nica Cadenas: Puerto Maldonado,
Madre de Dios; Roel Ore: Juliaca, Puno: Edward Pozo: Sullana, Piura;
Isabel Baza ´n and Stalin Vilcarromero: Iquitos; Julio Custodio: Cusco;
Favio Sarmiento: Pucallpa.
Disclaimers
The views expressed in this article are those of the authors and do not
necessarily reflect the official policy or position of the Department of the
Navy, Department of Defense, nor the U.S. Government.
Author Contributions
Conceived and designed the experiments: VALT JG TJK. Performed the
experiments: VO MEG IP EC RC JC SM EG JA SG CT. Analyzed the
data: VALT JG PVA JSA CVM JP JCA IP EC EG GC TJK. Contributed
reagents/materials/analysis tools: VO MEG. Wrote the paper: VALT JG
PVA JP GC TJK. Principal investigator: VALT. Critical revision of the
manuscript: PVA JSA. Critical review of the manuscript: GC. Authorized
the final version: TJK.
References
1. Simonsen L (1999) The global impact of influenza on morbidity and mortality.
Vaccine 17 Suppl 1: S3–10.
2. Ministerio de Salud P (2005) Plan Nacional de Preparacio ´n y Respuesta
Frente a una Potencial Pandemia de Influenza.
3. Laguna-Torres VA, Gomez J, Ocana V, Aguilar P, Saldarriaga T, et al. (2009)
Influenza-like illness sentinel surveillance in Peru. PLoS One 4: e6118.
4. Munayco CV, Gomez J, Laguna-Torres VA, Arrasco J, Kochel TJ, et al. (2009)
Epidemiological and transmissibility analysis of influenza A(H1N1)v in a
southern hemisphere setting: Peru. Euro Surveill 14.
5. Gomez J, Munayco C, Arrasco J, Suarez L, Laguna-Torres V, et al. (2009)
Pandemic influenza in a southern hemisphere setting: the experience in Peru
from May to September, 2009. Euro Surveill 14.
6. CDC (2009) CDC protocol of real-time RT-PCR for influenza A (H1N1), April
2009. In: INFLUENZA, editor: CDC.
7. Ministerio de Salud P (2005) Vigilancia Centinela de la Influenza y otros virus
respiratorios. Directiva Nu 057-MINSA/OGE-V01.
8. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, et al.
(2009) Pandemic potential of a strain of influenza A (H1N1): early findings.
Science 324: 1557–1561.
9. Nishiura H, Castillo-Chavez C, Safan M, Chowell G (2009) Transmission
potential of the new influenza A(H1N1) virus and its age-specificity in Japan.
Euro Surveill 14.
10. Chowell G, Miller MA, Viboud C (2008) Seasonal influenza in the United
States, France, and Australia: transmission and prospects for control. Epidemiol
Infect 136: 852–864.
11. Belshe RB (2004) Current status of live attenuated influenza virus vaccine in the
US. Virus Res 103: 177–185.
12. Frank AL, Taber LH (1983) Variation in frequency of natural reinfection with
influenza A viruses. J Med Virol 12: 17–23.
13. Anderson RM MR (1991) Infectious diseases of humans. New York: Oxford
University 3. Press.
14. Chile. MoH (2009) Influenza Government 2009 H1N1 pandemic. Weekly
Report. Week 32.
15. Chile. MoH (2010) Influenza pandemica (H1N1) 2009 Reporte situacion 2009.
Chile.
16. Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C,
et al. (2009) Severe respiratory disease concurrent with the circulation of H1N1
influenza. N Engl J Med 361: 674–679.
Influenza A (pH1N1) in Peru
PLoS ONE | www.plosone.org 8 July 2010 | Volume 5 | Issue 7 | e11719